243 related articles for article (PubMed ID: 1318830)
21. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking.
Lehr HA; Weyrich AS; Saetzler RK; Jurek A; Arfors KE; Zimmerman GA; Prescott SM; McIntyre TM
J Clin Invest; 1997 May; 99(10):2358-64. PubMed ID: 9153277
[TBL] [Abstract][Full Text] [Related]
22. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
[TBL] [Abstract][Full Text] [Related]
23. Combined effect of Web 2086 (Paf antagonist) and ketoprofen (Nsaid) on Paf-induced ex vivo platelet aggregation in bovine.
Bastos da Silva M; Herion F; Raskinet R; David JL; Gustin P; Lekeux P
Zentralbl Veterinarmed A; 1997 Apr; 44(2):65-71. PubMed ID: 9284631
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
[TBL] [Abstract][Full Text] [Related]
25. Effects of endothelin-1 on vascular permeability in the conscious rat: interactions with platelet-activating factor.
Filep JG; Sirois MG; Rousseau A; Fournier A; Sirois P
Br J Pharmacol; 1991 Dec; 104(4):797-804. PubMed ID: 1667286
[TBL] [Abstract][Full Text] [Related]
26. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
27. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
Herbert JM; Laplace MC; Maffrand JP
J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
[TBL] [Abstract][Full Text] [Related]
28. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
[TBL] [Abstract][Full Text] [Related]
29. A study of the effect of a platelet activating factor (PAF) receptor antagonist on antigen challenge of horses with chronic obstructive pulmonary disease.
Marr KA; Fairbairn SM; Page CP; Lees P; Cunningham FM
J Vet Pharmacol Ther; 1996 Jun; 19(3):233-7. PubMed ID: 8803882
[TBL] [Abstract][Full Text] [Related]
30. The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086.
Griffin K; Hong T; Levy JV
Biochem Biophys Res Commun; 1989 Apr; 160(1):263-7. PubMed ID: 2540748
[TBL] [Abstract][Full Text] [Related]
31. The effect of intravenous administration of WEB 2086 on PAF-induced platelet aggregation in healthy Friesian calves.
Bastos da Silva MB; Gustin P; Herion F; Raskinet R; David JL; Gougnard T; Plomteux G; Desmecht D; Lekeux P
Vet Res Commun; 1997 Oct; 21(7):521-31. PubMed ID: 9345719
[TBL] [Abstract][Full Text] [Related]
32. [Characterization of platelet-activating factor (PAF)-receptors in neutrophilic and eosinophilic granulocytes].
Ukena D; Dent G; Chanez P; Barnes PJ; Sybrecht GW
Pneumologie; 1990 Feb; 44 Suppl 1():531-2. PubMed ID: 2164200
[TBL] [Abstract][Full Text] [Related]
33. Increased neutrophil-endothelial adhesion induced by placental factors is mediated by platelet-activating factor in preeclampsia.
Wang Y; Adair CD; Weeks JW; Lewis DF; Alexander JS
J Soc Gynecol Investig; 1999; 6(3):136-41. PubMed ID: 10376269
[TBL] [Abstract][Full Text] [Related]
34. Characterization of receptors for platelet-activating factor on platelets, polymorphonuclear leukocytes and macrophages.
Stewart AG; Dusting GJ
Br J Pharmacol; 1988 Aug; 94(4):1225-33. PubMed ID: 2850058
[TBL] [Abstract][Full Text] [Related]
35. Long-lasting inhibitory activity of the hetrazepinic BN 50730 on exudation and cellular alterations evoked by PAF and LPS.
Pires AL; e Silva PM; Pasquale C; Castro-Faria-Neto HC; Bozza PT; Cordeiro RS; Rae GA; Braquet P; Lagente V; Martins MA
Br J Pharmacol; 1994 Nov; 113(3):994-1000. PubMed ID: 7858896
[TBL] [Abstract][Full Text] [Related]
36. Administration of a receptor antagonist for platelet-activating factor during equine endotoxaemia.
Carrick JB; Morris DD; Moore JN
Equine Vet J; 1993 Mar; 25(2):152-7. PubMed ID: 8385601
[TBL] [Abstract][Full Text] [Related]
37. Actions of PAF receptor antagonists in horses with the allergic skin disease sweet itch.
Foster AP; Lees P; Cunningham FM
Inflamm Res; 1995 Oct; 44(10):412-7. PubMed ID: 8564516
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological profile of UK-74,505, a novel and selective PAF antagonist with potent and prolonged oral activity.
Parry MJ; Alabaster VA; Cheeseman HE; Cooper K; deSouza RN; Keir RF
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):251-68. PubMed ID: 7812676
[TBL] [Abstract][Full Text] [Related]
39. The platelet activating factor receptor antagonist, RP 59227, blocks platelet activating factor receptors mediating liberation of reactive oxygen species in guinea pig macrophages and human polymorphonuclear leukocytes.
Floch A; Tahraoui L; Sedivy P; Cavero I
J Pharmacol Exp Ther; 1991 Aug; 258(2):567-75. PubMed ID: 1650834
[TBL] [Abstract][Full Text] [Related]
40. Platelet-activating factor (PAF) receptor-mediated calcium mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells: studies with BN50739, a new PAF antagonist.
Yue TL; Gleason MM; Gu JL; Lysko PG; Hallenbeck J; Feuerstein G
J Pharmacol Exp Ther; 1991 Apr; 257(1):374-81. PubMed ID: 1850473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
